Literature DB >> 28213804

Psoriasis and cardiovascular events: updating the evidence.

Line Raaby1, Ole Ahlehoff2, Annette de Thurah3,4.   

Abstract

So far, systematic reviews have suggested an increased risk of cardiovascular diseases (CVD) in psoriatic patients, though some results have been conflicting. The aim of this study was to update the current level of evidence through a systematic search in MEDLINE, EMBASE and Cochrane Central Register databases. In total, 13 high-quality observational studies estimating the incidence of CVD were included. Patients with mild psoriasis had an increased risk of stroke [Hazard ratio (HR) = 1.10, 95% CI: 1.0-1.19] and myocardial infarction (MI) (HR = 1.20, 95% CI: 1.06-1.35), but not cardiovascular death. The risks of both stroke (HR = 1.38, 95% CI: 1.20-1.60), MI (HR = 1.70, 95% CI: 1.18-2.43) and cardiovascular death (HR = 1.37, 95% CI: 1.13-1.67) were increased in patients with severe psoriasis. In conclusion, this updated meta-analysis confirmed that patients with psoriasis have an increased risk of CVD, especially those with severe psoriasis.

Entities:  

Keywords:  Cardiovascular death; Cardiovascular diseases; Meta-analysis; Myocardial infarction; Psoriasis; Stroke

Mesh:

Year:  2017        PMID: 28213804     DOI: 10.1007/s00403-016-1712-1

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  20 in total

Review 1.  Endothelial Dysfunction in Psoriasis: An Updated Review.

Authors:  Panagiota Anyfanti; Anastasia Margouta; Kyriakos Goulas; Maria Gavriilaki; Elizabeth Lazaridou; Aikaterini Patsatsi; Eugenia Gkaliagkousi
Journal:  Front Med (Lausanne)       Date:  2022-06-10

Review 2.  Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.

Authors:  Jin Bu; Ruilian Ding; Liangjia Zhou; Xiangming Chen; Erxia Shen
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 3.  Increased risk of stroke among patients with inflammatory bowel disease: A PRISMA-compliant meta-analysis.

Authors:  Yao Chen; Xiang Wang
Journal:  Brain Behav       Date:  2021-05-07       Impact factor: 2.708

4.  Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

Authors:  K B Gordon; M Lebwohl; K A Papp; H Bachelez; J J Wu; R G Langley; A Blauvelt; B Kaplan; M Shah; Y Zhao; R Sinvhal; K Reich
Journal:  Br J Dermatol       Date:  2021-11-24       Impact factor: 11.113

Review 5.  Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences.

Authors:  Wolf-Henning Boehncke
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

Review 6.  Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.

Authors:  Stephen Chu-Sung Hu; Cheng-Che E Lan
Journal:  Int J Mol Sci       Date:  2017-10-21       Impact factor: 5.923

7.  Association between physical activity and risk of prevalent psoriasis: A MOOSE-compliant meta-analysis.

Authors:  Qi Zheng; Xiao Ying Sun; Xiao Miao; Rong Xu; Tian Ma; Ya Nan Zhang; Hong Jin Li; Bin Li; Xin Li
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

8.  Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials.

Authors:  Bénédicte Champs; Yannick Degboé; Thomas Barnetche; Alain Cantagrel; Adeline Ruyssen-Witrand; Arnaud Constantin
Journal:  RMD Open       Date:  2019-01-24

Review 9.  GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk.

Authors:  Margery A Connelly; James D Otvos; Irina Shalaurova; Martin P Playford; Nehal N Mehta
Journal:  J Transl Med       Date:  2017-10-27       Impact factor: 5.531

10.  Psoriasis Severity-A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome.

Authors:  Melita Vuksic Polic; Maja Miskulin; Martina Smolic; Kristina Kralik; Ivan Miskulin; Maja Cigrovski Berkovic; Ines Bilic Curcic
Journal:  Int J Environ Res Public Health       Date:  2018-07-13       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.